Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'INNOCELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection (PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea.
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2017
At a glance
- Drugs T-lymphocyte cell therapy (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Green Cross Cell
- 23 Sep 2015 Protocol has been amended to change in primary endpoint and treatment arms, as per ClinicalTrials.gov record.
- 13 Aug 2013 Final results of the trial will be available soon, according to the media release.
- 13 Aug 2013 Mid-tern analysis results presented at the 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE), according to an Innocell media release.